CALC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CalciMedica Inc (CALC) is not a strong buy for a beginner investor with a long-term horizon at this time. The stock is currently facing significant challenges, including bearish technical indicators, lack of recent positive news or catalysts, and weak financial performance. While there is potential for recovery in the long term, the absence of clear growth drivers and the recent discontinuation of a major clinical trial make this a high-risk investment. A hold position is recommended until more clarity on future prospects emerges.
The technical indicators suggest a bearish trend. The MACD is positive but contracting, RSI is neutral at 34.318, and the moving averages indicate a bearish alignment (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 0.6, with resistance levels at 0.875 and 0.96. Overall, the technical outlook does not indicate a strong buy opportunity.
The absence of drug-related toxicity in the Phase 2 KOURAGE dataset is a positive development. Additionally, Oppenheimer maintains an Outperform rating, citing potential revenue opportunities from Auxora in acute pancreatitis.
The discontinuation of the Phase 2 KOURAGE clinical trial in acute kidney injury has removed a major catalyst for the stock. Analysts have downgraded the stock, and there are no significant trading trends or recent news to support a bullish outlook.
In Q4 2025, the company reported a net income loss of -$10.76M, an improvement of 152.70% YoY. However, revenue remains at 0, and EPS is negative at -0.68. The financial performance indicates ongoing challenges with no clear growth trends.
Analysts have mixed views. Oppenheimer lowered the price target from $20 to $10 but maintains an Outperform rating, citing potential in acute pancreatitis. H.C. Wainwright downgraded the stock to Neutral due to the discontinuation of the Phase 2 KOURAGE trial. Overall, sentiment is cautious with no strong buy signals.
